AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ANGO

AngioDynamics, Inc. Q1 2027 Earnings Call Summary

AngioDynamics reported Q1 2027 earnings, with MedTech segment revenue growing 13.2% YoY, now 49% of total revenue. Auryon saw 21st straight quarter of double-digit growth. NanoKnife adoption increased, with record procedure volumes. Full-year revenue guidance is $336M-$341M, with MedTech expected to dominate. Gross margin expanded 410 bps due to pricing and mix shift. Eric Honer appointed as new CEO. The company remains debt-free and expects positive cash flow for the year.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 4:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 5:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics, Inc. Q1 2027 Earnings Call Summary — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ANGONeutralHigh
01

Why it matters

The earnings call outlines growth drivers, FDA approvals, and strategic initiatives that shape near-term valuation.

02

Market read

First-report earnings guidance for AngioDynamics provides actionable data for traders focusing on medtech equities.

03

What to watch

Potential reimbursement expansions for NanoKnife and cost savings from Costa Rica transition may improve margins.

Relevance 8/10Novelty 8/10Timing: today

Background

AngioDynamics is executing a transformation shifting revenue toward higher-margin MedTech products.

Company-level read

Ticker impact

$ANGONeutralHigh confidence
Context

AngioDynamics provided Q1 2027 earnings call details and new full-year revenue guidance of $336M-$341M.

Expected impact

likely modest pressure as investors weigh mixed growth signals and capital sales volatility

Evidence & confidence

New guidance and segment performance are primary disclosures; traders can adjust positions based on the outlook.

Market effects

Sector

MedTech growth may benefit related device makers, while flat MedDevice segment could pressure peers.

Regional

U.S. medtech sector sees mixed signals; no immediate global ripple.

Global

Limited to healthcare device niche.

Counterpoint

What could challenge this read

Guidance could be a floor; upside potential if MedTech growth exceeds 15% and capital sales stabilize.

Key entities

  • Executive
    Eric Honer

    New President and CEO effective November 2.

  • Product
    NanoKnife

    Device transitioning to primary prostate care tool with BPH study.

Read at source← All news

StoryAngioDynamics posts Q1 FY2027 earnings beat and names new CEO

Also covered by

5 outlets

Related articles

$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

marketscreener.com
$ANGOMed

H.C. Wainwright cuts AngioDynamics stock price target to $18

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

investing.com
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Polic

AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.

gurufocus.com
$ANGOHigh

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

finance.yahoo.com